Will SOLS's RAS segment Adjusted EBITDA margin recover above 36% in FY2026?

RAS margin fell 370bps to 35.2% due to LGWP product mix shift. Committee converged on 36-38% stabilization range, meaning recovery above 36% is within the base case. However, LGWP transition is ongoing with legacy products continuing to phase out while LGWP ramps. Mid-single-digit EBITDA growth guidance suggests some margin improvement. Healthcare packaging destocking adds headwind. 36% is achievable but not certain.

I weight the downside risks more: LGWP products are inherently less differentiated per the committee debate, healthcare packaging recovery timing is uncertain, and nuclear revenue lumpiness within RAS adds margin volatility. Management mid-single-digit EBITDA growth guidance on low single-digit revenue implies margin expansion, but not necessarily at the segment level. Transaction costs persisting through FY2026 may not directly affect RAS margin but signal ongoing disruption.

FY2025 included significant LGWP transition acceleration AND healthcare packaging destocking, two headwinds that may moderate in FY2026. If destocking normalizes ($43M headwind partially reverses) and LGWP production scaling brings efficiency gains, 36%+ is plausible. The 5,700+ patents and brand strength provide some pricing support. Capacity expansion in nuclear (higher margin) could also help at the segment level.

More skeptical on margin recovery. The LGWP transition is inherently margin-dilutive with new products facing more competition and lower differentiation. 370bps compression in one year is significant, and the transition is not complete. Even the committee consensus of 36-38% required optimistic assumptions about production scaling benefits. The more likely outcome is margins stabilize in 34-36% range before potentially recovering to 36%+ over 2-3 years.

Mid-single-digit EBITDA growth on low single-digit revenue growth does imply margin expansion at the consolidated level. If RAS tracks the consolidated direction, some recovery is likely. But the 36% threshold is meaningful, 80bps above FY2025. Healthcare packaging normalization and nuclear revenue recovery could each contribute 50-100bps. Lean slightly below 50% given LGWP structural headwinds.

Lower confidence because the segment margin dynamics depend on LGWP product cost curves we lack visibility into. The thesis that LGWP margins improve with scale is reasonable but unverified. First standalone year means cost allocation changes could also affect segment reporting. Too many unknowns for high conviction in either direction.

Committee expects 36-38% stabilization. Management guides mid-single-digit EBITDA growth. Healthcare packaging destocking should moderate. 36% is achievable but depends on LGWP transition pace. Near coin-flip.

370bps compression is significant. LGWP transition is multi-year. Recovery above 36% in just one year after such sharp decline seems optimistic. More likely margins stabilize around 35-36% first.

Nuclear revenue recovery from FY2025 trough could help RAS margin. Healthcare packaging normalization also helps. But LGWP mix shift continues. Balanced to slightly below 50%.